<DOC>
	<DOCNO>NCT00875316</DOCNO>
	<brief_summary>Phytopharm plc develop Cogane™ new medicine treatment Parkinson 's disease ( PD ) . The purpose study find Cogane safe well tolerate healthy volunteer Parkinson 's disease patient determine difference way body deal Cogane ( pharmacokinetics ) two group . It expect study prove Cogane™ safe well tolerate provide u pharmacokinetic profile subject group .</brief_summary>
	<brief_title>Safety Tolerability Study Cogane™ Healthy Volunteers Parkinson 's Disease Patients</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<criteria>Key Inclusion Criteria ( Healthy Volunteers ) : Male &amp; Female healthy volunteer age 40 80 year time inform consent Females nonchildbearing potential General Good Health Key Exclusion Criteria ( Healthy Volunteers ) : No clinically significant relevant medical history Smoked within 3 month prior screen Use prescription nonprescription systemic topical medication ( include herbal remedy ) within 14 day first dose administration Key Inclusion Criteria ( Parkinson 's disease patient ) : Male &amp; Female Parkinson 's disease patient age 40 80 year time informed consent Must diagnosis idiopathic Parkinson 's disease accord UK Parkinson 's Disease Society Brain Bank criterion Subjects take Parkinson 's disease treatment stable regimen least 4 week prior screen Key Exclusion Criteria ( Parkinson 's disease patient ) : Diagnosis dementia Parkinson 's disease know genetic cause History surgical intervention Parkinson 's disease</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Parkinson 's disease</keyword>
	<keyword>Phase I</keyword>
</DOC>